CN102206599A - Oxygen-resistant acid-resistant Bifidobacterium longum - Google Patents
Oxygen-resistant acid-resistant Bifidobacterium longum Download PDFInfo
- Publication number
- CN102206599A CN102206599A CN 201110089493 CN201110089493A CN102206599A CN 102206599 A CN102206599 A CN 102206599A CN 201110089493 CN201110089493 CN 201110089493 CN 201110089493 A CN201110089493 A CN 201110089493A CN 102206599 A CN102206599 A CN 102206599A
- Authority
- CN
- China
- Prior art keywords
- resistant
- oxygen
- acid
- bifidobacterium longum
- preservation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241001608472 Bifidobacterium longum Species 0.000 title claims abstract description 35
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title claims abstract description 35
- 229940009291 bifidobacterium longum Drugs 0.000 title claims abstract description 35
- 239000001301 oxygen Substances 0.000 title claims abstract description 35
- 229910052760 oxygen Inorganic materials 0.000 title claims abstract description 35
- 239000002253 acid Substances 0.000 title claims abstract description 31
- 241000894006 Bacteria Species 0.000 claims abstract description 18
- 238000004321 preservation Methods 0.000 claims abstract description 12
- 238000009629 microbiological culture Methods 0.000 claims abstract description 3
- 241000186000 Bifidobacterium Species 0.000 abstract description 24
- 239000007788 liquid Substances 0.000 abstract description 8
- 238000000034 method Methods 0.000 abstract description 4
- 239000002609 medium Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 6
- 239000006041 probiotic Substances 0.000 description 6
- 235000018291 probiotics Nutrition 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000003833 bile salt Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- -1 glycerin Diesters Chemical class 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000003471 mutagenic agent Substances 0.000 description 2
- 231100000707 mutagenic chemical Toxicity 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241000186012 Bifidobacterium breve Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000005002 female reproductive tract Anatomy 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 150000002500 ions Chemical group 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000004767 rumen Anatomy 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明涉及一种耐氧耐酸性长双歧杆菌,其特征在于:名称为CC-1,分类名称Bifidobacterium longum,保藏编号为:CGMCC No.4730,保藏日期:2011年4月2日,保藏地址为:北京市朝阳区北辰西路1号院3号,保藏单位:中国微生物菌种保藏管理委员会普通微生物中心。本发明有效改善了双歧杆菌的生理生化性能,增强了双歧杆菌对氧和酸的耐受性,将耐氧耐酸长双歧杆菌在pH值4.0的PTYG液体培养基中于普通有氧条件下37℃培养,由倾注法活菌计数结果可知,耐氧耐酸长双歧杆菌CC-1的活菌数能达到4.7×107CFU/ml,该浓度对双歧杆菌制品的研究与应用将有极其重要的作用。
The invention relates to an oxygen-resistant and acid-resistant Bifidobacterium longum, characterized in that: the name is CC-1, the classification name is Bifidobacterium longum, the preservation number is: CGMCC No.4730, the preservation date is April 2, 2011, and the preservation address For: No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing. Preservation unit: General Microbiology Center of China Committee for the Collection of Microbial Cultures. The invention effectively improves the physiological and biochemical properties of bifidobacteria, enhances the tolerance of bifidobacteria to oxygen and acid, and puts oxygen-resistant and acid-resistant Bifidobacterium longum in a PTYG liquid medium with a pH value of 4.0 under normal aerobic conditions. Cultivated at 37°C, the number of viable bacteria of oxygen-resistant and acid-resistant Bifidobacterium longum CC-1 can reach 4.7×10 7 CFU/ml from the counting results of viable bacteria by the pouring method. has an extremely important role.
Description
技术领域technical field
本发明涉及食品科学技术领域,尤其是一种耐氧耐酸性长双歧杆菌。The invention relates to the technical field of food science, in particular to an oxygen-resistant and acid-resistant Bifidobacterium longum.
背景技术Background technique
2002年,FAO/WHO将益生菌定义为“活的,服用足够数量后对宿主具有健康影响的微生物”。作为益生菌的细菌应该具备以下条件:(1)对宿主有益;(2)无毒性作用和无致病作用;(3)能在消化道存活;(4)能适应胃酸和胆盐;(5)能在消化道表面定殖;(6)能够产生有用的酶类和代谢物;(7)在加工和贮存过程中能保持活性;(8)具有良好的感官特性。2005年5月29日我国家食品药品监督管理局颁布了《益生菌类保健食品申报与评审规定》,并公布了一批可用于保健食品的益生菌菌种包括:两歧双歧杆菌(Bifidobacterium bifidum)、婴儿双歧杆菌(Bifidobacterium infantis)、长双歧杆菌(Bifidobacterium longum)、短双歧杆菌(Bifidobacterium breve)、青春双歧杆菌(Bifidobacterium adolescentis)、德氏乳杆菌保加利亚种(Lactobacillus delbrueckii subsp.bulgaricus)、嗜酸乳杆菌(Lactobacillus acidophilus)、干酪乳杆菌干酪亚种(Lactobacillus casei subsp.Casei)、嗜热链球菌(Streptococcus thermophilus)、罗伊氏乳杆菌(Lactobacillus reuteri)。目前用于制造功能食品的益生菌主要是乳酸杆菌类和双歧杆菌类,不同类型的益生菌作用强弱是有差异的,相比而言,双歧杆菌调节胃肠道功能更强一些。In 2002, FAO/WHO defined probiotics as "live microorganisms that have health effects on the host after taking sufficient quantities". Bacteria as probiotics should meet the following conditions: (1) beneficial to the host; (2) non-toxic and non-pathogenic; (3) able to survive in the digestive tract; (4) able to adapt to gastric acid and bile salts; (5) ) can colonize the surface of the digestive tract; (6) can produce useful enzymes and metabolites; (7) can maintain activity during processing and storage; (8) have good sensory properties. On May 29, 2005, China's State Food and Drug Administration promulgated the "Regulations on the Declaration and Review of Probiotic Health Foods", and announced a batch of probiotic strains that can be used in health foods, including: Bifidobacterium bifidum bifidum), Bifidobacterium infantis, Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium adolescentis, Lactobacillus delbrueckii subsp. bulgaricus), Lactobacillus acidophilus, Lactobacillus casei subsp. Casei, Streptococcus thermophilus, Lactobacillus reuteri. At present, the probiotics used to make functional foods are mainly Lactobacillus and Bifidobacterium. Different types of probiotics have different effects. In comparison, Bifidobacteria are stronger in regulating the function of the gastrointestinal tract.
双歧杆菌广泛存在于人和暖体动物的肠道、女性生殖道及反刍动物的瘤胃等环境中,它在婴儿和成人的肠道内都占有很高的比例,是母乳喂养婴幼儿肠道的主要微生物。早在1899年,由法国巴斯德研究所的Henry Tissier第一次从母乳喂养婴幼儿的粪便中分离得到双歧杆菌,此后,它的益生作用越来越受到人们的重视,现在已经成为益生菌研究领域的焦点。双歧杆菌的保健功能包括:(1)抑制病原菌,防止腹泻和便秘,对腐败菌、病原性大肠埃希菌、金黄色葡萄球菌、痢疾志贺菌、变形菌等具有抑制作用;(2)防治高血压和动脉硬化,双歧杆菌可以将胆固醇转化为人体不吸收的类固醇,降低血液中胆固醇的浓度,对高血压和动脉硬化有一定的防治作用,双歧杆菌还可以降低血清胆固醇和甘油二酯,具有改善脂质代谢紊乱的作用;(3)营养作用,双歧杆菌能合成多种维生素,如VB1,VB2,VB6,VB12,叶酸,尼古酸,泛酸等,代谢产生的有机酸可降低环境中的pH值和Eb值,有利于二价铁、钙及VD的吸收;(4)免疫和抗衰老作用,激活机体免疫系统,使之保持免疫监视和免疫清除功能,不断地清除衰老、死亡的细胞及突变细胞,使机体不至因死亡细胞、废物堆积而衰老;双歧杆菌能增加血液中超氧化物歧化酶的活性和含量,从而减少自由基参与的氧化反应导致的机体衰老;(5)减少肠源性内毒素的产生和吸收,双歧杆菌在肠道内可吸收利用含氮有害物质,抑制产胺的腐败菌,降低肠道内的pH值,使氨变为难于吸收的离子型,达到降低血氨的功效,从而减小对肝的危害;(6)抑制肿瘤的作用,双歧杆菌可以激活机体的免疫系统中的巨噬细胞,增强免疫功能,减少体内癌诱变剂的含量,使产生癌诱变剂的酶失活。另外,肠道腐生菌在代谢中会产生许多胺类致癌物质,有的还能将一些致癌前体物转化为致癌物,双歧杆菌通过抑制腐生菌的生长和分解致癌物质而起到预防肠道癌的作用;(7)改善和调节肠道菌群失调,菌群失调(双歧杆菌大量减少)可导致肠道功能减退,儿童可引起迁延和复发性感染,高水平适宜的双歧杆菌在肠道通过可以阻止病原体的致病作用,从而就可以纠正肠菌群失调引起的腹泻。Bifidobacteria widely exist in the intestines of humans and warm-bodied animals, the female reproductive tract, and the rumen of ruminants. It occupies a high proportion in the intestines of infants and adults. main microorganisms. As early as 1899, Henry Tissier of the Pasteur Institute in France first isolated Bifidobacteria from the feces of breastfed infants. The focus of bacterial research. The health functions of bifidobacteria include: (1) inhibit pathogenic bacteria, prevent diarrhea and constipation, and have inhibitory effects on spoilage bacteria, pathogenic Escherichia coli, Staphylococcus aureus, Shigella dysenteriae, Proteus, etc.; (2) Prevention and treatment of hypertension and arteriosclerosis, bifidobacteria can convert cholesterol into steroids that are not absorbed by the human body, reduce the concentration of cholesterol in the blood, and have a certain preventive effect on hypertension and arteriosclerosis, bifidobacteria can also reduce serum cholesterol and glycerin Diesters have the effect of improving lipid metabolism disorders; (3) nutrition, bifidobacteria can synthesize a variety of vitamins, such as VB 1 , VB 2 , VB 6 , VB 12 , folic acid, nicotine, pantothenic acid, etc., metabolize The organic acid produced can reduce the pH value and Eb value in the environment, which is beneficial to the absorption of ferrous iron, calcium and vitamin D; (4) immune and anti-aging effects, activate the immune system of the body, so that it can maintain immune surveillance and immune clearance functions , constantly remove aging, dead cells and mutant cells, so that the body will not age due to dead cells and waste accumulation; Bifidobacteria can increase the activity and content of superoxide dismutase in the blood, thereby reducing the oxidation reaction involving free radicals (5) Reduce the production and absorption of intestinal-derived endotoxins. Bifidobacteria can absorb and utilize nitrogen-containing harmful substances in the intestines, inhibit spoilage bacteria that produce amines, reduce the pH value in the intestines, and make ammonia change. It is an ion type that is difficult to absorb, so as to achieve the effect of reducing blood ammonia, thereby reducing the harm to the liver; (6) inhibiting the effect of tumors, bifidobacteria can activate macrophages in the immune system of the body, enhance immune function, reduce The level of cancer mutagens in the body, which inactivates the enzymes that produce cancer mutagens. In addition, intestinal saprophytic bacteria can produce many amine carcinogens in their metabolism, and some can convert some carcinogenic precursors into carcinogens. Bifidobacteria prevent intestinal (7) Improving and regulating intestinal flora imbalance, flora imbalance (a large reduction of bifidobacteria) can lead to intestinal dysfunction, children can cause persistent and recurrent infections, high levels of suitable bifidobacteria Passing in the intestinal tract can prevent the pathogenic effect of pathogens, so that the diarrhea caused by intestinal flora imbalance can be corrected.
当然,人体内的双歧杆菌要在达到一定数量之后才能发挥其益生作用,目前普遍认为每克肠内含物中的活双歧杆菌量至少要达到1×107个左右,而且还要在其特定的肠道部位才发挥作用。影响双歧杆菌最终存活率的因素有很多,包括菌种自身、氧分压、pH值、胆盐含量等,双歧杆菌是专性厌氧菌,且不耐酸,在氧气和酸度较低的条件下,生长缓慢且容易死亡,造成培养的难度大,生产的成本高,给生产双歧杆菌制品的厂家带来很大的困难。Of course, the bifidobacteria in the human body must reach a certain amount before they can exert their beneficial effects. At present, it is generally believed that the amount of viable bifidobacteria in each gram of intestinal contents must reach at least 1×10 7 Its specific parts of the gut work. There are many factors that affect the final survival rate of bifidobacteria, including the strain itself, oxygen partial pressure, pH value, bile salt content, etc. Bifidobacteria are obligate anaerobic bacteria and are not acid-resistant. Under these conditions, the growth is slow and easy to die, which makes the cultivation difficult and the production cost is high, which brings great difficulties to the manufacturers of bifidobacterium products.
发明内容Contents of the invention
本发明的目的在于克服现有技术的不足之处,通过对长双歧杆菌进行连续的耐氧和耐酸驯化,得到耐氧耐酸性长双歧杆菌CC-1,本菌种培养后活菌数能达到4.7×107CFU/mL。The purpose of the present invention is to overcome the deficiencies of the prior art, by carrying out continuous oxygen-resistant and acid-resistant acclimatization to Bifidobacterium longum, obtain oxygen-resistant and acid-resistant Bifidobacterium longum CC-1, the number of viable bacteria after the culture of this strain It can reach 4.7×10 7 CFU/mL.
本发明的目的是通过以下技术方案实现的:The purpose of the present invention is achieved through the following technical solutions:
一种耐氧耐酸性长双歧杆菌,名称为CC-1,分类名称Bifidobacterium longum,保藏编号为:CGMCC No.4730,保藏日期:2011年4月2日,保藏地址为:北京市朝阳区北辰西路1号院3号,保藏单位:中国微生物菌种保藏管理委员会普通微生物中心。An oxygen-resistant and acid-resistant Bifidobacterium longum, the name is CC-1, the classification name is Bifidobacterium longum, the preservation number is: CGMCC No.4730, the preservation date is April 2, 2011, and the preservation address is: Beichen, Chaoyang District, Beijing No. 3, No. 1 Yard, West Road, preservation unit: General Microbiology Center of China Microbiological Culture Collection Management Committee.
而且,所述耐氧耐酸性长双歧杆菌CC-1的活菌数为4.7×107CFU/mL。Moreover, the number of viable bacteria of the oxygen-resistant and acid-resistant Bifidobacterium longum CC-1 is 4.7×10 7 CFU/mL.
本发明的优点和积极效果如下:Advantage of the present invention and positive effect are as follows:
本发明有效改善了双歧杆菌的生理生化性能,增强了双歧杆菌对氧和酸的耐受性,将耐氧耐酸长双歧杆菌在pH值4.0的PTYG液体培养基中于普通有氧条件下37℃培养,由倾注法活菌计数结果可知,耐氧耐酸长双歧杆菌CC-1的活菌数能达到4.7×107CFU/mL,该浓度对双歧杆菌制品的研究与应用将有极其重要的作用。The invention effectively improves the physiological and biochemical properties of bifidobacteria, enhances the tolerance of bifidobacteria to oxygen and acid, and puts oxygen-resistant and acid-resistant Bifidobacterium longum in a PTYG liquid medium with a pH value of 4.0 under normal aerobic conditions. Cultured at 37°C, according to the counting results of viable bacteria by the pouring method, the number of viable bacteria of oxygen-resistant and acid-resistant Bifidobacterium longum CC-1 can reach 4.7×10 7 CFU/mL. has an extremely important role.
附图说明Description of drawings
图1是本发明的耐氧耐酸长双歧杆菌CC-1和初始长双歧杆菌在pH值7.0的PTYG液体培养基中于厌氧条件下37℃培养后的菌体OD600值的变化曲线。Fig. 1 is the change curve of the OD 600 value of the thalline after the oxygen-resistant and acid-resistant Bifidobacterium longum CC-1 of the present invention and the initial Bifidobacterium longum are cultivated in PTYG liquid medium with a pH value of 7.0 under anaerobic conditions at 37°C .
图2是本发明的耐氧耐酸长双歧杆菌CC-1和初始长双歧杆菌在pH值7.0的PTYG液体培养基中于厌氧条件下37℃培养后的菌体pH值的变化曲线。Fig. 2 is the change curve of the bacterial cell pH value after the oxygen-resistant and acid-resistant Bifidobacterium longum CC-1 and initial Bifidobacterium longum of the present invention are cultured in PTYG liquid medium with a pH value of 7.0 at 37° C. under anaerobic conditions.
具体实施方式Detailed ways
下面结合实施例,对本发明进一步说明,下述实施例是说明性的,不是限定性的,不能以下述实施例来限定本发明的保护范围。Below in conjunction with the examples, the present invention is further described, the following examples are illustrative, not limiting, and the protection scope of the present invention cannot be limited by the following examples.
1.长双歧杆菌的驯化1. Acclimatization of Bifidobacterium longum
双歧杆菌基础培养基PTYG成分:大豆蛋白胨5g,胰蛋白胨5g,酵母浸膏10g,葡萄糖10g,L-半胱氨酸盐酸盐0.5g,微量盐溶液40mL,水1000mL,调pH值7.0。微量盐溶液成分为(1000mL水):CaCl2:0.2g,MgSO4·7H2O:0.48g,KH2PO4:1.0g,NaHCO3:10.0g,K2HPO4:1.0g,NaCl:2.0g。Bifidobacterium basal medium PTYG ingredients: soybean peptone 5g, tryptone 5g, yeast extract 10g, glucose 10g, L-cysteine hydrochloride 0.5g, trace salt solution 40mL, water 1000mL, adjust the pH value to 7.0. The composition of trace salt solution is (1000mL water): CaCl 2 : 0.2g, MgSO 4 7H 2 O: 0.48g, KH 2 PO 4 : 1.0g, NaHCO 3 : 10.0g, K 2 HPO 4 : 1.0g, NaCl: 2.0g.
初始菌株为实验室现有长双歧杆菌。The initial strain was Bifidobacterium longum existing in the laboratory.
接种量:5%,培养温度:37℃Inoculum size: 5%, culture temperature: 37°C
(1)长双歧杆菌的耐氧驯化:通过逐渐增加培养基中氧气分压的方法来驯化,在每个氧气分压梯度下传代5-8次反复驯化,再接种到下一个氧气分压梯度中培养,每次耐氧驯化后挑选耐氧的长双歧杆菌单菌落。(1) Oxygen-resistant acclimatization of Bifidobacterium longum: Acclimate by gradually increasing the oxygen partial pressure in the medium, subculture 5-8 times under each oxygen partial pressure gradient and repeatedly acclimatize, and then inoculate to the next oxygen partial pressure Gradient cultivation, and after each oxygen-resistant acclimatization, a single colony of aerobic-resistant Bifidobacterium longum was selected.
本发明通过以下途径来增加培养基中的氧气分压:一是在厌氧箱中培养,每次增加0.02个氧分压,最后再转到普通培养条件下培养;二是在改变培养环境的同时,在培养器皿一定的条件下,逐渐减少装液量,即采用100mL的厌氧瓶,装液量依次为100mL、80mL、60mL、40mL、20mL。The present invention increases the partial pressure of oxygen in the culture medium through the following approaches: the one is to cultivate in an anaerobic box, increase the partial pressure of oxygen by 0.02 each time, and finally transfer to common culture conditions for cultivation; the other is to change the cultivation environment At the same time, under certain conditions of the culture vessel, gradually reduce the liquid volume, that is, use a 100mL anaerobic bottle, and the liquid volume is 100mL, 80mL, 60mL, 40mL, and 20mL.
(2)长双歧杆菌的耐酸驯化:将耐氧驯化完得到的耐氧长双歧杆菌再进行耐酸驯化,通过逐渐降低培养基pH值的方法驯化,pH值依次为7.0、6.5、6.0、5.5、5.0、4.5、4.0,每个pH值梯度传代5-8次,反复驯化,再接种到下一个pH值,每次耐酸驯化后挑选耐酸的长双歧杆菌单菌落,最终得到生长能力最强的CC-1。(2) Acid-resistant acclimation of Bifidobacterium longum: The oxygen-resistant Bifidobacterium longum obtained after the oxygen-resistant acclimation is then subjected to acid-resistant acclimation, by gradually reducing the pH value of the medium for acclimation, and the pH values are 7.0, 6.5, 6.0, 5.5, 5.0, 4.5, 4.0, each pH value gradient was subcultured 5-8 times, repeatedly acclimated, and then inoculated to the next pH value, and selected acid-resistant Bifidobacterium longum single colonies after each acid-resistant acclimation, and finally obtained the best growth ability. Strong CC-1.
2.耐氧耐酸长双歧杆菌的生长特性2. Growth characteristics of oxygen-resistant and acid-resistant Bifidobacterium longum
通过分析比较初始菌和耐氧耐酸长双歧杆菌生长的菌体OD600值、pH值、及活菌数等指标,从而可知耐氧耐酸长双歧杆菌的生长特性。The growth characteristics of oxygen-resistant and acid-resistant Bifidobacterium longum can be known by analyzing and comparing the OD 600 value, pH value, and the number of viable bacteria of the initial bacteria and the growth of oxygen-resistant and acid-resistant Bifidobacterium longum.
由耐氧耐酸长双歧杆菌CC-1和初始菌同时在pH值7.0的PTYG液体培养基中于厌氧条件下37℃培养后的菌体OD600值和pH值的变化曲线可以看出,耐氧耐酸的菌株生长情况要好,并且延滞期略有缩短,活菌数相对较高,产酸能力也有所提高。It can be seen from the change curves of the OD 600 value and pH value of the bacteria after the oxygen-resistant and acid-resistant Bifidobacterium longum CC-1 and the initial bacteria are simultaneously cultured in the PTYG liquid medium with a pH value of 7.0 at 37°C under anaerobic conditions, The oxygen-resistant and acid-resistant strains grow better, and the lag period is slightly shortened, the number of viable bacteria is relatively high, and the acid-producing ability is also improved.
将耐氧耐酸长双歧杆菌CC-1和初始菌同时在pH值4.0的PTYG液体培养基中于普通有氧条件下37℃培养,由倾注法活菌计数结果可知,耐氧耐酸长双歧杆菌的活菌数能达到4.7×107CFU/mL,而初始菌株只能达到2.1×103CFU/mL。The oxygen-resistant and acid-resistant Bifidobacterium longum CC-1 and the initial bacteria were simultaneously cultured in the PTYG liquid medium with a pH value of 4.0 under normal aerobic conditions at 37°C. According to the counting results of viable bacteria by the pouring method, the oxygen-resistant and acid-resistant Bifidobacterium longum The viable count of bacilli can reach 4.7×107CFU/mL, while the initial strain can only reach 2.1×103CFU/mL.
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011100894937A CN102206599B (en) | 2011-04-11 | 2011-04-11 | Oxygen-resistant acid-resistant Bifidobacterium longum |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011100894937A CN102206599B (en) | 2011-04-11 | 2011-04-11 | Oxygen-resistant acid-resistant Bifidobacterium longum |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102206599A true CN102206599A (en) | 2011-10-05 |
CN102206599B CN102206599B (en) | 2012-07-25 |
Family
ID=44695662
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011100894937A Expired - Fee Related CN102206599B (en) | 2011-04-11 | 2011-04-11 | Oxygen-resistant acid-resistant Bifidobacterium longum |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102206599B (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103266077A (en) * | 2013-06-04 | 2013-08-28 | 神舟太空产品高科技成果推广中心集团有限公司 | Space-induced efficient bifidobacterium longum, application thereof, and preparation method of capsule preparation thereof |
CN103266076A (en) * | 2013-06-04 | 2013-08-28 | 神舟太空产品高科技成果推广中心集团有限公司 | Space-induced efficient bifidobacterium bifidum and application thereof as well as preparation method of capsule preparation of space-induced efficient bifidobacterium bifidum |
CN104531590A (en) * | 2015-01-14 | 2015-04-22 | 贵州大学 | Fragrant pig derived cholesterol-assimilating and oxygen-resistant bifidobacterium BZll |
CN104560829A (en) * | 2015-01-14 | 2015-04-29 | 贵州大学 | Fragrance pig source cholesterol-reducing and oxygen-resistant bifidobacterium BZ25 |
CN104630099A (en) * | 2015-01-19 | 2015-05-20 | 北京工商大学 | Bifidobacterium longum strain and application thereof in preparing active Bifidobacterium fermented beverage |
CN105112333A (en) * | 2015-08-31 | 2015-12-02 | 江南大学 | Bifidobacterium longum with good intestinal tract colonizing ability and screening method and application of bifidobacterium longum |
CN105641682A (en) * | 2016-02-26 | 2016-06-08 | 南昌大学 | Application of Bifidobacterium longum protein in improvement of antibiotics sensitivity of Salmonella typhimurium |
CN107280014A (en) * | 2017-08-02 | 2017-10-24 | 安徽金源药业有限公司 | It is a kind of to promote the compound probiotic protein powder of Instestinal motility |
CN107319567A (en) * | 2017-08-02 | 2017-11-07 | 安徽金源药业有限公司 | It is a kind of to promote the compound probiotic chewable tablets of Instestinal motility |
CN109527209A (en) * | 2018-12-27 | 2019-03-29 | 共放鸣 | A kind of probiotic feed additive and preparation method thereof for realizing waste zero discharge culture |
CN111876352A (en) * | 2020-07-28 | 2020-11-03 | 科兴生物制药股份有限公司 | Oxygen-resistant acid-resistant bifidobacterium infantis and screening method thereof |
CN111902154A (en) * | 2018-01-29 | 2020-11-06 | 精密生物集团有限公司 | Bifidobacterium longum NCIMB 41676 |
CN111918663A (en) * | 2018-01-29 | 2020-11-10 | 精密生物集团有限公司 | Bifidobacterium longum NCIMB 41676 |
CN112625933A (en) * | 2019-09-24 | 2021-04-09 | 南京盛德生物科技研究院有限公司 | Bifidobacterium longum mutant strain H8 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61185182A (en) * | 1985-02-14 | 1986-08-18 | Meiji Milk Prod Co Ltd | Mutant strain of bifidus and cultivation composition thereof |
US6306638B1 (en) * | 1996-10-22 | 2001-10-23 | Food Industry Research And Development Institute | Mutant bifidobacteria strains with acid, bile salt and oxygen tolerance |
-
2011
- 2011-04-11 CN CN2011100894937A patent/CN102206599B/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61185182A (en) * | 1985-02-14 | 1986-08-18 | Meiji Milk Prod Co Ltd | Mutant strain of bifidus and cultivation composition thereof |
US6306638B1 (en) * | 1996-10-22 | 2001-10-23 | Food Industry Research And Development Institute | Mutant bifidobacteria strains with acid, bile salt and oxygen tolerance |
Non-Patent Citations (2)
Title |
---|
《中国食品学报》 19980331 周家春,徐玉佩 双歧杆菌的耐氧驯化 22-28 1-2 第2卷, 第1期 * |
《福州大学学报(自然科学版)》 20030630 林娟 等 耐氧耐酸双歧杆菌的选育 368-371 1-2 第31卷, 第3期 * |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103266076A (en) * | 2013-06-04 | 2013-08-28 | 神舟太空产品高科技成果推广中心集团有限公司 | Space-induced efficient bifidobacterium bifidum and application thereof as well as preparation method of capsule preparation of space-induced efficient bifidobacterium bifidum |
CN103266077B (en) * | 2013-06-04 | 2014-08-06 | 神舟太空产品高科技成果推广中心集团有限公司 | Space-induced efficient bifidobacterium longum, application thereof, and preparation method of capsule preparation thereof |
CN103266076B (en) * | 2013-06-04 | 2014-10-29 | 神舟太空产品高科技成果推广中心集团有限公司 | Space-induced efficient bifidobacterium bifidum and application thereof as well as preparation method of capsule preparation of space-induced efficient bifidobacterium bifidum |
CN103266077A (en) * | 2013-06-04 | 2013-08-28 | 神舟太空产品高科技成果推广中心集团有限公司 | Space-induced efficient bifidobacterium longum, application thereof, and preparation method of capsule preparation thereof |
CN104531590B (en) * | 2015-01-14 | 2017-12-08 | 贵州大学 | One plant of fragrant pig source property norcholesterol, oxytolerant Bifidobacterium BZ11 |
CN104531590A (en) * | 2015-01-14 | 2015-04-22 | 贵州大学 | Fragrant pig derived cholesterol-assimilating and oxygen-resistant bifidobacterium BZll |
CN104560829A (en) * | 2015-01-14 | 2015-04-29 | 贵州大学 | Fragrance pig source cholesterol-reducing and oxygen-resistant bifidobacterium BZ25 |
CN104560829B (en) * | 2015-01-14 | 2017-11-14 | 贵州大学 | One plant of fragrant pig source property norcholesterol, oxytolerant Bifidobacterium BZ25 |
CN104630099A (en) * | 2015-01-19 | 2015-05-20 | 北京工商大学 | Bifidobacterium longum strain and application thereof in preparing active Bifidobacterium fermented beverage |
CN105112333A (en) * | 2015-08-31 | 2015-12-02 | 江南大学 | Bifidobacterium longum with good intestinal tract colonizing ability and screening method and application of bifidobacterium longum |
CN105641682A (en) * | 2016-02-26 | 2016-06-08 | 南昌大学 | Application of Bifidobacterium longum protein in improvement of antibiotics sensitivity of Salmonella typhimurium |
CN105641682B (en) * | 2016-02-26 | 2019-02-01 | 南昌大学 | A kind of bifidobacterium longum protein is used to be promoted the application of salmonella typhimurium Antibiotic Sensitivity |
CN107319567A (en) * | 2017-08-02 | 2017-11-07 | 安徽金源药业有限公司 | It is a kind of to promote the compound probiotic chewable tablets of Instestinal motility |
CN107280014A (en) * | 2017-08-02 | 2017-10-24 | 安徽金源药业有限公司 | It is a kind of to promote the compound probiotic protein powder of Instestinal motility |
CN111902154A (en) * | 2018-01-29 | 2020-11-06 | 精密生物集团有限公司 | Bifidobacterium longum NCIMB 41676 |
CN111918663A (en) * | 2018-01-29 | 2020-11-10 | 精密生物集团有限公司 | Bifidobacterium longum NCIMB 41676 |
CN111918663B (en) * | 2018-01-29 | 2024-10-11 | 精密生物集团有限公司 | Bifidobacterium longum NCIMB 41676 |
CN109527209A (en) * | 2018-12-27 | 2019-03-29 | 共放鸣 | A kind of probiotic feed additive and preparation method thereof for realizing waste zero discharge culture |
CN112625933A (en) * | 2019-09-24 | 2021-04-09 | 南京盛德生物科技研究院有限公司 | Bifidobacterium longum mutant strain H8 |
CN111876352A (en) * | 2020-07-28 | 2020-11-03 | 科兴生物制药股份有限公司 | Oxygen-resistant acid-resistant bifidobacterium infantis and screening method thereof |
Also Published As
Publication number | Publication date |
---|---|
CN102206599B (en) | 2012-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102206599B (en) | Oxygen-resistant acid-resistant Bifidobacterium longum | |
Timmerman et al. | Monostrain, multistrain and multispecies probiotics—A comparison of functionality and efficacy | |
CN102304489B (en) | Lactobacillus reuteri strain and application thereof | |
CN104830731B (en) | One strain has plant lactobacillus AB-1 and the application thereof of broad-spectrum antibacterial characteristic | |
CN110564638A (en) | Lactobacillus reuteri with probiotic characteristics and application thereof | |
WO2022110727A1 (en) | Application of lactobacillus paracasei et-22 in improving intestinal bacterial infection resistance and intestinal immunity | |
CN101974463B (en) | Lactobacillus reuteri and composite viable bacteria preparation thereof | |
CN104522648B (en) | A kind of quadruple probiotic preparation and its application | |
CN117660253B (en) | Lactobacillus rhamnosus FMBL L23004 CNN, yoghurt starter, yoghurt and application thereof | |
WO2025092264A1 (en) | Streptococcus salivarius subsp.thermophilus vb331 and use thereof | |
CN106222158A (en) | A kind of microcapsule preparation method embedding lactobacillus | |
CN115322932B (en) | Lactobacillus plantarum with anti-alcohol and sobering-up capabilities and application thereof | |
CN115232768B (en) | A kind of Lactobacillus paracasei JN-8 and its application | |
CN105420150A (en) | Lactobacillus acidophilus and application thereof | |
Yin et al. | Isolation and identification of the dominant Lactobacillus in gut and faeces of pigs using carbohydrate fermentation and 16S rDNA analysis | |
CN119307425B (en) | Bifidobacterium animalis subspecies lactis BLa79 and application, product and method thereof | |
CN115851494A (en) | A strain of Lactobacillus plantarum NHE-LpE5 and its application | |
CN115181682A (en) | Lactobacillus fermentum with high organic zinc enrichment | |
CN117917475A (en) | Lactobacillus plantarum P16 for regulating intestinal flora, application, product and method thereof | |
CN110577907A (en) | A kind of animal bifidobacteria and application thereof | |
CN115484968A (en) | Stimulation of growth of intestinal bifidobacteria | |
CN119410554B (en) | Bifidobacterium animalis subspecies ZYhyy-003 and metazoan preparation and application thereof | |
CN103705543A (en) | Manure-borne compound probiotics soluble powder for animals and preparation method thereof | |
CN115119940B (en) | Application of lactobacillus acidophilus LA85 and bifidobacterium lactis BLa80 in inhibiting helicobacter pylori | |
CN103820357A (en) | Long bifidobacterium and function thereof for prevention and treatment of food allergy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120725 Termination date: 20180411 |